89 ROCOPETIN

24 DEC 1998

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFIC FORM PTO-1390 (REV 10-05) TRANSMITTAL LETTER TO THE UNITED STATES OMRF143 CIP2 DESIGNATED/ELECTED OFFICE (DO/EO/US) U.S. APPLICATION NO. (If known, see 37 CFR 1.5) CONCERNING A FILING UNDER 35 U.S.C. 371 PRIORIT INTERNATIONAL FILING DATE INTERNATIONAL APPLICATION NO. PCT/US95/08331 30 June 1995 30 June TITLE OF INVENTION Antibodies to Lipoproteins and Apolipoproteins and Methods of Use Thereof APPLICANT(S) FOR DO/EO/US KOREN, Eugen and KOSCEC Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 4. X A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are transmitted herewith (required only if not transmitted by the International Bureau). have been transmitted by the International Bureau. have not been made; however, the time limit for making such amendemnts has NOT expired. have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. X A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. A substitute specification. A change of power of attorney and/or address letter. 16. X Other items or information: Copy of published application Verified Statement Claiming Small Entity Status

U.S. APPLICATION NO. (if known, see 17 CFR 1.5) INTERNATIONAL APPLICATION NO.			ATTORNEY'S DOCKET NUMBER						
	PCT/US95/08331		OMRF1	43 CIP2					
17. X The following fees are submitted:			CALCULATIO	NS PTO USE ONLY					
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):									
Search Report has been prepared by the EPO or JPO \$910.00									
International preliminary examination fee paid to USPTO (37 CFR 1.482)				·					
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))\$770.00									
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO\$1040.00									
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)			·						
ENTER APPROPRIATE BASIC FEE AMOUNT =			\$ 910.00)					
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 months from the earliest claimed priority date (37 CFR 1.492(e)).			s						
CLAIMS NUMBER FILED	NUMBER EXTRA	RATE							
Total claims 44 - 20 =	24	X \$22.00	\$ 528.00)					
Independent claims 6 - 3 =	3	×80.00	\$ 240.00						
MULTIPLE DEPENDENT CLAIM(S) (if app	licable)	+ 260.00	\$						
TOTAL OF ABOVE CALCULATIONS =			\$1,678.00	 					
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement									
must also by filed (Note 37 CFR 1.9, 1.27, 1.28).			839.00						
SUBTOTAL =			\$ 839.00)					
Processing fee of \$130.00 for furnishing the English translation later than 20 30 imonths from the earliest claimed priority date (37 CFR 1.492(f)).			\$						
TOTAL NATIONAL FEE =			\$ 839.00						
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$ 40.00	7					
TOTAL FEES ENCLOSED =			\$ 879.00						
:			Amount to be: refunded	S					
		ł	charged	- 5					
			charged						
a. A check in the amount of \$879.00 to cover the above fees is enclosed. b. Please charge my Deposit Account No in the amount of \$ to cover the above fees.									
A duplicate copy of this sheet is enclosed.									
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 01-2507. A duplicate copy of this sheet is enclosed.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.									
(N. 2									
			MI						
			rea L. Pabst						
					1201 West Peachtree S		NAME		
					Atlanta, Georgia 30309-3450		284		
	REGISTRA		TION NUMBER						
••									



08/765324 89 REFIPTO 24 DEC 1996

IN THE U.S. RECEIVING OFFICE FOR THE PATENT COOPERATION TREATY

Applicants:

KOREN, Eugen and KOSCEC, Mirna

International Application No:

PCT/US95/08331

International Filing Date:

30 June 1995

U.S. Serial No:

Filed:

24 December 1996

Express Mail Label No:

EM470184783US

Date of Deposit:

24 December 1996

For:

Antibodies to Lipoproteins and Apolipoproteins and Methods

of Use Thereof

Box PCT Assistant Commissioner for Patents Washington, D.C. 20231


EXPRESS MAIL TRANSMITTAL LETTER FOR PATENT APPLICATION AND CERTIFICATE OF MAILING

Sir:

Pursuant to 35 U.S.C. § 371 and 37 C.F.R. § 1.10, applicant encloses a Transmittal Letter to the United States Designated/Elected Office (DO/EO/US), a copy of International Application No. PCT/US95/08331 entitled "Antibodies to Lipoproteins and Apolipoproteins and Methods of Use Thereof", filed in the U.S. Receiving Office for the PCT on 30 June 1995, a Preliminary Amendment, executed Declaration and Power of Attorney, Assignment and Recordation Form Cover Sheet, Verified Statement Claiming Small Entity Status, and a check in the amount of \$879.00 to cover the filing and Assignment recordation fees.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 01-2507. A duplicate copy of this request is enclosed.

This application is being filed on 24 December 1996, by mailing the Transmittal Letter to Box PCT, Assistant Commissioner for Patents, Washington, D.C. 20231 via the United States Postal Service "Express Mail Post Office to Addressee" Service under 37



C.F.R. § 1.10. The Express Mail label number appears in the heading of this paper which is attached to the Transmittal Letter.

All correspondence concerning this application should be mailed to:

Patrea L. Pabst, Esq. Arnall Golden & Gregory 2800 One Atlantic Center 1201 West Peachtree Street Atlanta, Georgia 30309-3450

Respectfully submitted,

Patrea L. Pabst Reg. No. 31,284

Date: 24 December 1996

ARNALL GOLDEN & GREGORY 2800 One Atlantic Center 1201 West Peachtree Street Atlanta, Georgia 30309-3450 404/873-8794

CERTIFICATE OF MAILING UNDER 37 CFR § 1.10

I hereby certify that this Express Mail Transmittal Letter for Patent Application and any documents referred to as attached therein are being deposited with the United States Postal Service on this date, 24 December 1996, in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, Mailing Label Number EM470184783US addressed to Box PCT, Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: 24 December 1996

Robert/I/Copeland